Galien Golden Jubilee Forum USA 2021

Oct. 28th, 2021
9AM – 10AM

In-person registrationLive broadcast registration

Ann Graybiel, Institute Professor, Department of Brain and Cognitive Science, MIT

Diana Gallagher, Head of External Innovation, Biogen
Dan Grossman,
Managing Director and Senior Partner, Boston Consulting Group
Kelsey Martin, Director, Simons Foundation Autism Research Initiative (SFARI)
Michel Pairet, Member of the Board of Managing Directors – Innovation, Boehringer Ingelheim


Ann Graybiel
Institute Professor, Department of Brain and Cognitive Science

Ann M. Graybiel is an Institute Professor at the Massachusetts Institute of Technology, where she and her laboratory are actively investigating neural circuits that modulate mood, motivation and movement. These neural circuits are vulnerable in neurologic and neuropsychiatric conditions ranging from Parkinson’s disease to anxiety, depression and abnormally repetitive behavioral disturbances. Her group interacts extensively with clinicians as well as other basic scientists across several disciplines and is identifying molecular genetic markers of these circuits, with the goal of contributing to clinical medicine. On the basis of her work, Graybiel was elected to the National Academy of Sciences of the USA (1988), to the American Academy of Arts and Sciences (1991), and to the Institute of Medicine of the USA (1994). She was awarded the Dow Award in 2002, the Prix Plasticité Neuronale IBSEN in 2005, and the Vanderbilt Prize in 2008. In 2001, Graybiel was awarded the National Medal of Science of the United States, the nation’s highest science award. In 2012, Graybiel received the prestigious Kavli Prize in Neuroscience, bestowed by the King of Norway.

Diana Gallagher, M.D.
Head of External Innovation

Diana Gallagher, M.D., leads the External Innovation group at Biogen. Her group’s mission is to seek, evaluate, and source new opportunities for Biogen’s portfolio, which accelerates new medicines for patients with serious unmet needs. External Innovation covers opportunities in all global territories, across all therapeutic modalities, and multiple disease areas. Working with amazing colleagues across Biogen, the External Innovation team has been able to bring 20 innovations into the portfolio in 2020. In her 6+ years at Biogen, Dr. Gallagher has worked across discovery and clinical development with a focus on new and emerging areas for Biogen, including ophthalmology, immunology, neuropsychiatry, pain, and more.

Prior to Biogen, Dr. Gallagher worked in Early Clinical Development at Merck on oral, IV, and inhaled products across a range of clinical indications. Before working in industry, she completed an M.D. at Johns Hopkins, a Masters in Medical Sciences at Harvard Medical School, along with an Internal Medicine residency and Pulmonary and Critical Care fellowship at the Harvard hospitals. In addition to clinical time as an ICU physician, her research was focused on endothelial barrier dysfunction.

Dan Grossman
Managing Director and Senior Partner
Boston Consulting Group

Dan Grossman joined the Chicago office of the Boston Consulting Group in 2003, and serves as an advisor to numerous biopharma, med tech, patient advocacy, and other non-profit health care organizations. His focus is on innovation & growth strategy and environment-shaping for new-to-world therapies and diagnostics. Dan has worked extensively on innovative opportunities in the neuroscience space, spanning neurodegenerative disease such as Alzheimer’s and Parkinson’s, neurovascular interventional procedures, pain therapies, migraine treatments, and psychiatric treatments in the emerging field of psychedelic medicine. Within BCG, Dan is responsible for Health Care Practice Areas portfolio of proprietary data and tools that support a broad range of client engagements. Dan holds a PhD in mathematics from Princeton University, and prior to joining BCG, was on the faculty of the mathematics department of the University of Chicago.

Kelsey Martin
Simons Foundation Autism Research Initiative (SFARI)

Kelsey Martin joined the Simons Foundation in September 2021. She previously served as Dean of the David Geffen School of Medicine at UCLA, where she was also a faculty member in the Departments of Biological Chemistry and Psychiatry. Her research program addresses the molecular and cell biology of long-term neuronal plasticity and memory, and focuses on the transcriptional and post-transcriptional gene regulatory mechanisms that underlie experience-dependent synaptic plasticity. In recognition of her research accomplishments, she was elected to the National Academy of Medicine and the American Academy of Arts and Sciences in 2016. As Dean, Dr. Martin established programs in precision health and computational medicine, and developed a series of interdepartmental research initiatives spanning basic through clinical research.

Dr. Martin earned her bachelor’s degree in English and American Literature and Language at Harvard University, her MD and PhD in Molecular Biophysics and Biochemistry at Yale University, and did her postdoctoral training with Eric Kandel at Columbia University. She served as a Peace Corps volunteer in maternal and child health in Zaire (now the Democratic Republic of Congo) in the 1980s, inspiring her to pursue a career in medicine and biomedical research.

Michel Pairet
Member of the Board of Managing Directors – Innovation
Boehringer Ingelheim

He is in charge of Research, non-clinical Development, Patents, Business Development and Licensing, Translational Medicine and Clinical Pharmacology, and the Corporate Venture Fund and, as such, is responsible for Boehringer Ingelheim´s internal and external strategic product sourcing.

During his career, Michel has held several positions in Research and Development. With his team, he has been involved in the discovery and development of several important medicines that address diseases with a high medical need. These include:
Nintedanib/ Ofev® (first-in-class fibrokinase inhibitor for the treatment of Idiopathic Pulmonary Fibrosis (IPF; FDA Breakthrough designation) and several other Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)).
Dabigatran/ Pradaxa® (first-in-class novel oral anticoagulant for Stroke Prevention in Atrial Fibrillation: SPAF), and idarucizumab/ Praxbind® (first specific reversal agent available for a novel oral anticoagulant).
Empagliflozin/ Jardiance® (First anti-diabetic drug to demonstrate cardiovascular risk reduction in a dedicated cardiovascular outcome study)

All of these compounds were discovered in-house at Boehringer Ingelheim. In parallel, under Michel´s leadership, a specific focus was to access external innovation. This is illustrated by important partnerships with Academic teams and Biotech companies. These collaborations have generated development compounds, which today significantly contribute to Boehringer Ingelheim’s development pipeline, characterized by a high share of projects with first in class and breakthrough potential, in the areas of oncology, cardio-metabolic diseases, inflammatory and respiratory diseases, psychiatric diseases, and retinopathies.

Michel´s R&D strategy is based on three pillars: “1) Core Therapeutic Areas, to build on our strengths, by focusing on disease areas for which we have built a strong expertise over time. 2) Scientific Platforms, to build on synergies based on scientific mechanisms and technology platforms with potential in multiple disease areas, e.g. immune modulation, fibrosis, regenerative medicine, and 3) Research Beyond Borders, little smart bets in external innovation to explore emerging science beyond our current therapeutic area focus, and prepare a timely and efficient entry into new medical and scientific fields”.

Michel holds a Doctorate in Veterinary Medicine, a PhD and a Professorship in Physiology and Pharmacology, from the University of Toulouse, France. He has been issued several patents and has published several key scientific publications and book chapters.

Jay Stamatis
Vice President, Head of Business Development and Acquisitions

Jay Stamatis joined AbbVie in December 2016 with a diverse biotech and pharma experience base spanning more than 20 years. Jay and the business development & acquisitions team he leads have executed a large variety of transactions, ranging from the acquisition of Allergan in 2019 to a multitude of product development, collaboration, option or technology platform deals across AbbVie’s key therapeutic areas.

Prior to joining AbbVie, he was the Vice President of Business Development at Atara Bio, a publicly-traded oncology and cell therapy company in the San Francisco Bay Area.  Preceding his tenure at Atara Bio, Jay worked at Acerta Pharma, another Bay Area oncology start-up, now a subsidiary of AstraZeneca, and Onyx Pharmaceuticals, until its acquisition by Amgen.  Jay also spent a number of years at Amgen and Eli Lilly in a variety of business development and commercial leadership roles.

Jay earned his Bachelor Degree in History from Tulane University and a Master of Business Administration Degree from Washington University in St. Louis.